Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

ERα is required for suppressing OCT4-induced proliferation of breast cancer cells via DNMT1/ISL1/ERK axis.

Jin X, Li Y, Guo Y, Jia Y, Qu H, Lu Y, Song P, Zhang X, Shao Y, Qi D, Xu W, Quan C.

Cell Prolif. 2019 Jul;52(4):e12612. doi: 10.1111/cpr.12612. Epub 2019 Apr 22.

PMID:
31012189
2.

Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.

Li H, Pan GF, Jiang ZZ, Yang J, Sun LX, Zhang LY.

Acta Pharmacol Sin. 2015 May;36(5):606-13. doi: 10.1038/aps.2014.162. Epub 2015 Apr 13.

3.

[Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].

Zhang WJ, Xu DF, Fan QX, Wu XA, Wang F, Wang R, Wang LX.

Zhonghua Zhong Liu Za Zhi. 2012 Sep;34(9):645-51. doi: 10.3760/cma.j.issn.0253-3766.2012.09.002. Chinese.

PMID:
23159075
4.

DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis.

Pathania R, Ramachandran S, Elangovan S, Padia R, Yang P, Cinghu S, Veeranan-Karmegam R, Arjunan P, Gnana-Prakasam JP, Sadanand F, Pei L, Chang CS, Choi JH, Shi H, Manicassamy S, Prasad PD, Sharma S, Ganapathy V, Jothi R, Thangaraju M.

Nat Commun. 2015 Apr 24;6:6910. doi: 10.1038/ncomms7910.

5.

Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.

Zhang W, Wang L, Fan Q, Wu X, Wang F, Wang R, Ma Z, Yang J, Lu SH.

Oncol Rep. 2011 Sep;26(3):621-8. doi: 10.3892/or.2011.1352. Epub 2011 Jun 17.

PMID:
21687957
6.

MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.

Chen F, Luo N, Hu Y, Li X, Zhang K.

Cell Physiol Biochem. 2018;47(5):2147-2158. doi: 10.1159/000491526. Epub 2018 Jul 5.

7.

ERα propelled aberrant global DNA hypermethylation by activating the DNMT1 gene to enhance anticancer drug resistance in human breast cancer cells.

Si X, Liu Y, Lv J, Ding H, Zhang XA, Shao L, Yang N, Cheng H, Sun L, Zhu D, Yang Y, Li A, Han X, Sun Y.

Oncotarget. 2016 Apr 12;7(15):20966-80. doi: 10.18632/oncotarget.8038.

8.

A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.

Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L.

Cancer Prev Res (Phila). 2012 Jun;5(6):864-73. doi: 10.1158/1940-6207.CAPR-11-0575. Epub 2012 Apr 11.

9.

[Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].

[No authors listed]

Zhonghua Zhong Liu Za Zhi. 2015 Apr;37(4):251-7. Chinese.

PMID:
26462888
10.

[Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].

Fan J, Lu JS, Yin WJ, Lei W, Wu FY, Wu J, Hou YF, Li DQ, Di GH, Shen ZZ, Shao ZM.

Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):886-9. Chinese.

PMID:
17533736
11.

MicroRNA-22 inhibits proliferation, invasion and metastasis of breast cancer cells through targeting truncated neurokinin-1 receptor and ERα.

Liu X, Zhang L, Tong Y, Yu M, Wang M, Dong D, Shao J, Zhang F, Niu R, Zhou Y.

Life Sci. 2019 Jan 15;217:57-69. doi: 10.1016/j.lfs.2018.11.057. Epub 2018 Nov 28.

PMID:
30502362
12.

Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway.

Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu F, Tu T, Sun L, Zhu W, Zhou F, Qi W, Hu J, Chen H, Sun X.

Oncol Rep. 2015 Sep;34(3):1469-77. doi: 10.3892/or.2015.4109. Epub 2015 Jul 3.

PMID:
26151310
13.

Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.

Song X, Wei Z, Shaikh ZA.

Toxicol Appl Pharmacol. 2015 Aug 15;287(1):26-34. doi: 10.1016/j.taap.2015.05.010. Epub 2015 May 23.

14.

SMAD2 Inactivation Inhibits CLDN6 Methylation to Suppress Migration and Invasion of Breast Cancer Cells.

Lu Y, Wang L, Li H, Li Y, Ruan Y, Lin D, Yang M, Jin X, Guo Y, Zhang X, Quan C.

Int J Mol Sci. 2017 Aug 30;18(9). pii: E1863. doi: 10.3390/ijms18091863.

15.

Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.

Du J, Zhou N, Liu H, Jiang F, Wang Y, Hu C, Qi H, Zhong C, Wang X, Li Z.

PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.

16.
17.

Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway.

Ho JY, Chang FW, Huang FS, Liu JM, Liu YP, Chen SP, Liu YL, Cheng KC, Yu CP, Hsu RJ.

PLoS One. 2016 Feb 4;11(2):e0148301. doi: 10.1371/journal.pone.0148301. eCollection 2016.

18.

Shugan Liangxue Decoction () Down-Regulates Estrogen Receptor α Expression in Breast Cancer Cells.

Zhou N, Han SY, Chen YZ, Zhou F, Zheng WX, Li PP.

Chin J Integr Med. 2018 Jul;24(7):518-524. doi: 10.1007/s11655-015-2123-4. Epub 2016 Jan 6.

PMID:
26740221
19.

Tumor-suppressive effects of psoriasin (S100A7) are mediated through the β-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells.

Deol YS, Nasser MW, Yu L, Zou X, Ganju RK.

J Biol Chem. 2011 Dec 30;286(52):44845-54. doi: 10.1074/jbc.M111.225466. Epub 2011 Oct 20.

20.

Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.

Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO.

Mol Cancer. 2013 Feb 4;12:9. doi: 10.1186/1476-4598-12-9.

Supplemental Content

Support Center